Publications by authors named "X Treton"
Inflammatory bowel diseases cause chronic intestinal inflammation, including Crohn's disease (CD) and ulcerative colitis (UC). Prostaglandin E-major urinary metabolite (PGE-MUM) is a urine biomarker for disease activity in IBD. This study evaluated PGE-MUM performance for predicting an active disease in patients with CD and UC.
View Article and Find Full Text PDFBackground: Early complicated Crohn's disease (CD) may require ileal resection as first-line treatment.
Aim: To evaluate the long-term outcomes of patients who underwent early ileal resection.
Methods: We conducted a retrospective study in two inflammatory bowel diseases (IBD) referral centres, including patients with ileocaecal resection and segmental ileal resection within 5 years of CD diagnosis.
Article Synopsis
- Anti-TNFα therapy has transformed the treatment of inflammatory bowel disease (IBD), but it poses a risk for developing active tuberculosis (TB) and potential complications like immune reconstitution inflammatory syndrome (IRIS).
- A French retrospective study analyzed 36 IBD patients with TB treated with anti-TNFα, finding a high incidence of disseminated TB and a significant rate of IRIS, particularly in those with miliary TB.
- Most patients resumed anti-TNFα treatment safely after managing TB, with a favorable overall recovery rate, indicating that restarting this therapy can be an effective approach.
Background: Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis [UC], but head-to-head trials are lacking.
Aim: We aimed to compare the effectiveness of vedolizumab and ustekinumab after anti-tumour necrosis factor [anti-TNF] failure in UC patients.
Patients And Methods: In this multicentre study, we included consecutive adult patients with UC, with partial Mayo score >2 and prior anti-TNF exposure, treated with vedolizumab or ustekinumab between January 2019 and August 2022.
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and relapsing-remitting multiple sclerosis (MS) and available as part of routine care in accredited center. HSCT is also recommended, with varying levels of evidence, as an alternative treatment for several ADs, when refractory to conventional therapy, including specific cases of connective tissue diseases or vasculitis, inflammatory neurological diseases, and more rarely severe refractory Crohn's disease. The aim of this document was to provide guidelines for the current indications, procedures and follow-up of HSCT in ADs.
View Article and Find Full Text PDF